|
In
the following you will find some basic information useful to understand
the molecular aspects of CVD and the most promising ongoing therapeutic
approaches within EVGN:
EVGN
researchers are working hard to find out what can go wrong in our heart
and to develop new ways to fight the most common heart diseases. But
they have new strategies in their sleeves: the knowledge that come from
the human genome project and the new breakthrough techniques from
biotechnology and cell biology.
Genomics, proteomics and complete
human genome have opened up new horizons for molecular understanding of
cardiovascular disease, for identifying new diagnostic measurements and
developing new pharmacological gene- and cell-based therapies.
This big effort is being carried out by several scientists from 10 different countries.
In the EVGN project are involved 37 research groups, which means 252
researchers and 100 students at work to defeat the scourge of
cardiovascular disease.
Skills
and expertise within the EVGN consortium are highly heterogeneous and
complementary. This is an added value that allows the scientists to
address cardiovascular disease (CVD) from three major different
perspectives.
The areas of interest are:
Early endothelial dysfunctions
Prevention of plaque instability
Therapeutic Angiogenesis
Each of the three sectors integrates the post-genomic research with the
more established biomedical and biotechnological approaches to
cardiovascular disease, and shows great potential for the development
of new diagnostic and therapeutic strategies that will provide
permanent benefits for diseased people. Some EVGN teams have already
moved from the bench to the clinical practice, developing clinical
trials on human patients.
|
